

WO 2005/004592

1/7

PCT/IB2004/002374




Figure 1

WO 2005/004592

PCT/IB2004/002374

2/7




**b****c**

Figure 2

WO 2005/004592

3/7

PCT/IB2004/002374







a**b**


Figure 3

WO 2005/004592

PCT/IB2004/002374

4/7

Figure 4



WO 2005/004592

5/7

PCT/IB2004/002374

HLA-A2+DR1+CI-CII-AC anti-PreS2 response following a pcmv S2/S immunization




Figure 5

WO 2005/004592

6/7

PCT/IB2004/002374

HLA-A2+DR1+CI-CII-T CD4 proliferative response to
HLA-DR1 restricted epitopes following immunization
with pcmv S2-S





Figure 6

SUBSTITUTE SHEET (RULE 26)

WO 2005/004592

7/7

PCT/IB2004/002374

HLA-A2+ DR1+ Cl- CII-mice T CD8 cytotoxic
response to the HLA-A2 restricted HBS (348-357)
peptide following an immunization with pcmv S2/S




Figure 7